Effect of Glibenclamide Combined with Medical Nutrition Support on Blood Glucose Control and Pregnancy Outcome in Patients with Gestational Diabetes
Objective To observe and explore the clinical effect of glibenclamide combined with medical nutrition support in patients with gestational diabetes,and the influence of blood glucose control and pregnancy outcome.Methods A total of 80 patients with gestational diabetes received by our hospital from January 2022 to January 2023 were selected as research objects,and they were divided into a control group and an observation group using a random number table method,with 40 cases in each group.After admission,all patients received routine basic treatment.On this basis,the control group was treated with medical nutritional support,while the observation group was treated with medical nutritional support and added with glibenclamide.Compare the excellent blood glucose control rates,gestational body mass,blood glucose levels,insulin levels,pregnancy outcomes,and neonatal outcomes between two groups.Results The excellent rate of blood glucose control in the observation group was 92.50%,which was higher than 72.50%of the control group,and the difference was statistically significant(P＜0.05).Before treatment,there was no difference in Body Mass Index(BMI),Fasting Plasma Glucose(FPG),Fasting Insulin(FINS),and Hemoglobin A1c(HbA1c)between the two groups of patients(P＞0.05);after treatment,the observation group had lower pregnancy BMI(26.03±1.52)kg/㎡,FPG(6.23±0.99)mmol/L,FINS(11.01±1.62)mU/L,and HbA1c(6.16±0.71)%compared to the control group(28.61±1.73)kg/㎡,(7.74±0.91)mmol/L,(13.76±1.58)mU/L,and(7.08±0.75)%,and the differences were statistically significant(P＜0.05).The observation group had a premature birth rate of 22.50%,a cesarean section rate of 32.50%,an abnormal amniotic fluid rate of 12.50%,an incidence of premature rupture of membranes of 17.50%,an incidence of postpartum hemorrhage of 22.50%,and an incidence of postpartum infection of 15.00%,all were lower than the control group's 45.00%,55.00%,32.50%,37.50%,50.00%,and 37.50%,and the differences were statistically significant(P＜0.05).The incidence of fetal distress in the observation group was 10.00%,the incidence of neonatal asphyxia was 2.50%,the incidence of neonatal hypoglycemia was 7.50%,the incidence of neonatal infection was 5.00%,and the incidence of neonatal hyperbilirubinemia was 2.50%,all lower than the control group's 32.50%,20.00%,30.00%,25.00%,and 22.50%,and the differences were statistically significant(P＜0.05).Conclusion Glibenclamide can significantly improve the effect of blood glucose control,improve the body mass during pregnancy,reduce the fasting insulin level,optimize the pregnancy outcome and improve the birth quality of the population in diabetes patients with pregnancy on the basis of medical nutrition support treatment.
NETL
NSTL
万方数据
